Dal Alert!

Receive alerts from Dalhousie by text message.

X

Urological Oncology Research

Leading the way in urological cancer research

The Department of Urology is an innovative leader in urological oncology research. In addition to investigating cancer prevention and early detection, our researchers are also evaluating new agents, biomarkers and new technologies for the treatment of urological cancers. We're also developing new techniques to improve the safety and effectiveness of cancer surgeries.

Our basic science and clinical research efforts cover:

  • early detection and cancer prevention
  • minimally invasive surgical intervention
  • effective whole-body therapies for locally advanced and metastatic disease

Lead faculty researchers in urological oncology

Clinical trials in urological oncology

New trials

  • MAST_01:  A randomized, double-blind, placebo-controlled trial of Metformin in reducing progression among men on expectant management for low risk prostate cancer: the MAST (Metformin Active Surveillance Trial) study
  • Hypothermia: A randomized controlled trial of renal hypothermia during partial nephrectomy
  • TACT: Tranexamic Acid during Cystectomy Trial (TACT) pilot study
  • BNIT: A randomized, double-blind, phase 3 efficacy trial of PROSTVAC-V/F +/- GM-CSF in men with symptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer
  • CRONOS II: Canadian real life evaluation of the effect of diet and exercise in prostate cancer patients managed with Lupron: (CRONOS II)
  • PROSPER: A multinational, phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of Enzalutamide in patients with nonmetastatic castration resistant prostate cancer

Ongoing trials

  • Bladder Cancer Biomarker: A non-invasive epigenetic urinary biomarker panel for the early detection of bladder cancer
  • FIT: A phase IV, randomized, multicentre efficacy and safety study comparing 10 months versus 4 months of degarelix (Firmagon®) therapy in prolonging the off treatment interval in men with non-metastatic prostate cancer receiving intermittent androgen deprivation therapy for biochemical recurrence following radical local therapy
  • CRONOS: Canadian real life evaluation of the effectiveness of Lupron in the management of prostate cancer

Closing trials

  • 147: A randomized, double-blind, placebo-controlled, multicentre phase 3 study of Denosumab on prolonging bone metastasis-free survival in men with hormone refractory prostate cancer
  • 560: A double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in subjects with non-metastatic prostate cancer receiving Denosumab for bone loss due to androgen-deprivation therapy